Volume 79, Issue 1 supplement | Drugs

Home
Drugs
Volumes and issues
Volume 79, Issue 1 supplement

Drugs

Publishing model:: Hybrid

Submit your manuscript

Search all Drugs articles

Volume 79, Issue 1 supplement

February 2019

l-Ornithine l-Aspartate (LOLA) for the Treatment of Hepatic Encephalopathy in Cirrhosis: Novel Insights and Translation to the Clinic

Issue Editor:

Roger Butterworth

7 articles in this issue

l-Ornithine l-Aspartate (LOLA) for the Treatment of Hepatic Encephalopathy in Cirrhosis: Novel Insights and Translation to the Clinic
Roger F. Butterworth
Editorial 31 January 2019 Pages: 1 - 3
Hepatic Encephalopathy: Definition, Clinical Grading and Diagnostic Principles
Karin Weissenborn
Review Article Open access 31 January 2019 Pages: 5 - 9
Impact of Hepatic Encephalopathy in Cirrhosis on Quality-of-Life Issues
Sara Montagnese
Jasmohan S. Bajaj
Review Article Open access 31 January 2019 Pages: 11 - 16
Hepatic Encephalopathy in Cirrhosis: Pathology and Pathophysiology
Roger F. Butterworth
Review Article Open access 31 January 2019 Pages: 17 - 21
Pharmacokinetic and Pharmacodynamic Properties of l-Ornithine l-Aspartate (LOLA) in Hepatic Encephalopathy
Gerald Kircheis
Stefan Lüth
Review Article Open access 31 January 2019 Pages: 23 - 29
l-Ornithine l-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses
Roger F. Butterworth
Mark J. W. McPhail
Review Article Open access 31 January 2019 Pages: 31 - 37
l-Ornithine l-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease
Ali Canbay
Jan-Peter Sowa
Research Article Open access 31 January 2019 Pages: 39 - 44